Showing 40,301 - 40,320 results of 102,370 for search '(( 5 ((((a decrease) OR (we decrease))) OR (mean decrease)) ) OR ( 5 fold decrease ))', query time: 1.98s Refine Results
  1. 40301

    Data_Sheet_1_A pharmacokinetic study on red ginseng with furosemide in equine.docx by Young Beom Kwak (17445099)

    Published 2023
    “…The C<sub>max</sub>, AUC<sub>0−t</sub>, and AUC<sub>0−∞</sub> of furosemide was significantly increased in the experimental group (p < 0.05), while the CL, V<sub>z</sub>, and V<sub>ss</sub> was decreased (p < 0.05, p < 0.01). …”
  2. 40302

    Image1_Resveratrol has an Overall Neuroprotective Role in Ischemic Stroke: A Meta-Analysis in Rodents.TIF by Jianyang Liu (9632387)

    Published 2021
    “…Quality assessment was performed using a 10-item checklist. Studies quality scores ranged from 3 to 8, with a mean value of 5.94. …”
  3. 40303
  4. 40304

    Comparative Proteomic Profiling of 3T3-L1 Adipocyte Differentiation Using SILAC Quantification by Sunkyu Choi (2141545)

    Published 2020
    “…We report protein changes to the proteome profiles, with 354 proteins exhibiting significant increase and 56 proteins showing decrease in our statistical analysis. …”
  5. 40305

    Competition with TESA and trypomastigote protein extract demonstrates that Apt-L44 binds to a parasite biomarker. by Rana Nagarkatti (90297)

    Published 2014
    “…(<b>A</b>) In the presence of TESA, biotinylated aptamer is sequestered by its target and cannot interact with the target present in the coated plasma, causing a decrease in signal levels represented by % inhibition. …”
  6. 40306
  7. 40307

    <i>Bs</i>Fra alters the H/D exchange of <i>Bs</i>SufS and <i>Bs</i>SufU upon binding the <i>Bs</i>SufS/<i>Bs</i>SufU complex. by Bastian Blauenburg (715579)

    Published 2016
    “…Changes in <b>(F)</b> the SufU α5-helix and <b>(G)</b> the Cys41-loop as a function of deuterium uptake over time. …”
  8. 40308

    Influence of dietary and physical activity restriction on pediatric adenotonsillectomy postoperative care in Brazil: a randomized clinical trial by Denise Manica (4702840)

    Published 2018
    “…Mean age in months (A = 79.5; SD = 33.9/B = 81.1; SD = 32.6) and sex (A = 58% male; B = 64.4% male) were equivalent between groups. …”
  9. 40309

    Temporal trends in Human T-Lymphotropic virus 1 (HTLV-1) associated myelopathy/tropical spastic paraparesis (HAM/TSP) incidence in Martinique over 25 years (1986-2010) by Stephane Olindo (4976189)

    Published 2018
    “…Age-standardized 5-year incidence rates significantly decreased by 69% and 87% in 2001–2005 and 2006–2010 study periods. …”
  10. 40310
  11. 40311

    Regulation by a shared sRNA synchronizes the temporal induction of mRNA expression. by Jörn Matthias Schmiedel (141779)

    Published 2012
    “…The heatmaps show simulation results for a regulatory scenario where a coordinate, step-like increase (C) or decrease (panel D) in both mRNA synthesis rates is accompanied by a step-like change in the sRNA synthesis rate in the opposite direction; this counter-regulation assumption was necessary to eliminate delay phases, and to obtain the same steady states in sRNA and sRNA-less systems. …”
  12. 40312

    Effect of Paricalcitol vs Calcitriol on Hemoglobin Levels in Chronic Kidney Disease Patients: A Randomized Trial by Eleonora Riccio (451487)

    Published 2015
    “…Therefore, we conducted a study to determine whether paricalcitol, compared to calcitriol, improves anemia in patients with chronic kidney disease (CKD).…”
  13. 40313

    Table_1_The Fate of Altertoxin II During Tomato Processing Steps at a Laboratory Scale.DOCX by Hannes Puntscher (6834581)

    Published 2019
    “…We observed a significant decrease in altertoxin II concentrations in samples stored at room temperature and particularly those undergoing thermal treatment by employing a validated LC-MS/MS method. …”
  14. 40314
  15. 40315

    Supplemental Figure 10 from Herbacetin Is a Novel Allosteric Inhibitor of Ornithine Decarboxylase with Antitumor Activity by Dong Joon Kim (280038)

    Published 2023
    “…Vehicle, herbacetin (100 mg/kg B.W. p.o. or 2 mg/kg B.W. i.p.) or DFMO (1 g/kg B.W. p.o.) was administered by gavage or intraperitoneal injection 5 times per week for 5 weeks. (A) DFMO significantly decreased hearing (measured as prepulse inhibition or PPI) on day 35. …”
  16. 40316

    <i>HNF1A</i> is necessary for reprogramming and sufficient in combination with two interchangeable transcription factors. by Kamen P. Simeonov (588591)

    Published 2014
    “…(C–E) Consistent loss of <i>AFP</i> induction with removal of <i>HNF1A</i> (blue) from reprogramming cocktails, 6TF, 5TF, and 4TF, with little or no decrease of induction due to removal of other factors. …”
  17. 40317

    DataSheet1_Examining the paradoxical effects of kratom: a narrative inquiry.PDF by Kirsten E. Smith (10716529)

    Published 2023
    “…Five of the 10 participants met DSM-5-based criteria for kratom-use disorder (3 mild, 1 moderate, 1 severe, by symptoms counts). …”
  18. 40318

    Table 1_A retrospective analysis of 38,652 amniotic fluid karyotype.xlsx by Jianyu Ren (11429773)

    Published 2025
    “…Chromosome breakage was most common in chromosomes Y and 1, whereas deletions were most frequently detected in chromosomes X and 5. Isochromosomes mainly appeared in a mosaic form in chromosome X. …”
  19. 40319

    Supplementary Material for: Urinary Apolipoprotein C3 Is a Potential Biomarker for Alzheimer’s Disease by Watanabe Y. (4129684)

    Published 2020
    “…We previously reported on the comprehensive profile of the urinary proteome of AD patients and identified proteins estimated to be significantly increased or decreased in AD patients by a label-free quantification method. …”
  20. 40320

    Effects of the AMPA Antagonist ZK 200775 on Visual Function: A Randomized Controlled Trial by Richard Bergholz (244473)

    Published 2010
    “…<div><h3>Background</h3><p>ZK 200775 is an antagonist at the α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor and had earned attention as a possible neuroprotective agent in cerebral ischemia. …”